Cancer pathogenesis and therapy最新文献

{"title":"Bone metastasis is a late-onset and unfavorable event in survivors of gastric cancer after radical gastrectomy: Results from a clinical observational cohort","authors":"Cheng Zhang ,&nbsp;Xiaopeng Zhang ,&nbsp;Chong Feng ,&nbsp;Yahui Yang ,&nbsp;Minmin Xie ,&nbsp;Ying Feng ,&nbsp;Zhijun Wu ,&nbsp;Hui Xu ,&nbsp;Changhao Wu ,&nbsp;Tai Ma","doi":"10.1016/j.cpt.2023.11.003","DOIUrl":"10.1016/j.cpt.2023.11.003","url":null,"abstract":"<div><h3>Background</h3><p>The timing and incidence of recurrent bone metastasis (BM) after radical gastrectomy in patients with gastric cancer (GC) as well as the survival of these patients were not fully understood. The aim of this study was to analyze the data of an observational GC cohort and identify patients who underwent curative gastrectomy and had recurrent BM to describe and clarify the pattern and profile of BM evolution after surgery.</p></div><div><h3>Methods</h3><p>Data were retrieved from a hospital-based GC cohort, and patients who underwent upfront radical gastrectomy were selected. The time points of specific organ metastatic events were recorded, and the person-year incidence rate of metastatic events was calculated. The latency period of BM events after gastrectomy was measured and compared with that of the other two most common metastatic events, liver metastasis (LM) and distant lymph node metastasis (LNM), using analysis of variance. Propensity score matching and subgroup analysis were used for sensitivity analysis.</p></div><div><h3>Results</h3><p>A total of 1324 GC cases underwent radical gastrectomy between January 2011 and December 2021. Of these, 67 BM, 218 LM, and 248 LNM occurred before the last follow-up. The incidence of BM events was 1.7/100 person-years, which was approximately 3-fold lower than that of LM and distant LNM events (5.5 and 6.3 per 100 person-years, respectively). BM events had a significantly longer latency (median time, 16.5 months) than LM and LNM events (11.1 and 12.0 months, respectively). Recurrent BM led to a worse prognosis (median survival, 4.5 months) than those of LM and LNM events (median survival, 7.7 and 7.1 months, respectively). However, no difference in overall survival after gastrectomy was observed among the groups.</p></div><div><h3>Conclusions</h3><p>Compared with other common metastatic events, BM in GC after gastrectomy is a late-onset event indicating poor survival.</p></div><div><h3>Trial registration</h3><p>No. ChiCTR1800019978; <span>http://www.chictr.org.cn/</span><svg><path></path></svg>.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000927/pdfft?md5=44a805ff0115c91ffd88551b42f13026&pid=1-s2.0-S2949713223000927-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135763761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases on primary bone marrow lymphoma","authors":"Zining Wang ,&nbsp;Lu Sun ,&nbsp;Yue Wang ,&nbsp;Haoran Chen ,&nbsp;Hongbin Pu ,&nbsp;Bo Yang ,&nbsp;Xuechun Lu","doi":"10.1016/j.cpt.2023.10.001","DOIUrl":"10.1016/j.cpt.2023.10.001","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000836/pdfft?md5=ec1083df58b222e3247b5e3235119349&pid=1-s2.0-S2949713223000836-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135605570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experimental models for cancer brain metastasis","authors":"Zihao Liu ,&nbsp;Shanshan Dong ,&nbsp;Mengjie Liu ,&nbsp;Yuqiang Liu ,&nbsp;Zhiming Ye ,&nbsp;Jianhao Zeng ,&nbsp;Maojin Yao","doi":"10.1016/j.cpt.2023.10.005","DOIUrl":"10.1016/j.cpt.2023.10.005","url":null,"abstract":"<div><p>Brain metastases are a leading cause of cancer-related mortality. However, progress in their treatment has been limited over the past decade, due to an incomplete understanding of the underlying biological mechanisms. Employing accurate <em>in vitro</em> and <em>in vivo</em> models to recapitulate the complexities of brain metastasis offers the most promising approach to unravel the intricate cellular and physiological processes involved. Here, we present a comprehensive review of the currently accessible models for studying brain metastasis. We introduce a diverse array of <em>in vitro</em> and <em>in vivo</em> models, including cultured cells using the Transwell system, organoids, microfluidic models, syngeneic models, xenograft models, and genetically engineered models. We have also provided a concise summary of the merits and limitations inherent to each model while identifying the optimal contexts for their effective utilization. This review serves as a comprehensive resource, aiding researchers in making well-informed decisions regarding model selection that align with specific research questions.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000873/pdfft?md5=815b1f0ff05fad760d1811a05b60dfc1&pid=1-s2.0-S2949713223000873-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136152804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors","authors":"Chuandong Hou ,&nbsp;Zining Wang ,&nbsp;Xuechun Lu","doi":"10.1016/j.cpt.2023.08.001","DOIUrl":"10.1016/j.cpt.2023.08.001","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs) are employed in immunotherapeutic applications for patients with weakened immune systems and can improve the ability of T cells to kill cancer cells. Although ICIs can potentially treat different types of cancers in various groups of patients, their effectiveness may differ among older individuals. The reason ICIs are less effective in older adults is not yet clearly understood, but age-related changes in the immune system, such as immunosenescence and inflammation, may play a role. Therefore, this review focuses on recent advances in understanding the effects of immunosenescence and inflammation on the efficacy of ICIs.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000484/pdfft?md5=de94deaec420e00e46c23da7252d8e24&pid=1-s2.0-S2949713223000484-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82353641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preimplantation genetic testing for embryos predisposed to hereditary cancer: Possibilities and challenges","authors":"Mohammed H. Albujja ,&nbsp;Maher Al-Ghedan ,&nbsp;Lakshmidevi Dakshnamoorthy ,&nbsp;Josep Pla Victori","doi":"10.1016/j.cpt.2023.05.002","DOIUrl":"10.1016/j.cpt.2023.05.002","url":null,"abstract":"<div><p>Preimplantation genetic testing (PGT), which was developed as an alternative to prenatal genetic testing, allows couples to avoid pregnancies with abnormal chromosomes and the subsequent termination of the affected fetus. Originally used for early onset monogenic conditions, PGT is now used to prevent various types of inherited cancer conditions based on the development of PGT technology, assisted reproductive techniques (ARTs), and <em>in vitro</em> fertilization (IVF). This review provides insights into the potential benefits and challenges associated with the application of PGT for hereditary cancer and provides an overview of the existing literature on this test, with a particular focus on the current challenges related to laws, ethics, counseling, and technology. Additionally, this review predicts the future potential applications of this method. Although PGT may be utilized to predict and prevent hereditary cancer, each case should be comprehensively evaluated. The motives of couples must be assessed to prevent the misuse of this technique for eugenic purposes, and non-pathogenic phenotypes must be carefully evaluated. Pathological cases that require this technology should also be carefully considered based on legal and ethical reasoning. PGT may be the preferred treatment for hereditary cancer cases; however, such cases require careful case-by-case evaluations. Therefore, this study concludes that multidisciplinary counseling and support for patients and their families are essential to ensure that PGT is a viable option that meets all legal and ethical concerns.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000265/pdfft?md5=664fbd9bca1e903ebc7ed8bf7ce4bd1c&pid=1-s2.0-S2949713223000265-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81330991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial note to previously published articles","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000563/pdfft?md5=23362d3c2e3531332b15e418446a4d96&pid=1-s2.0-S2949713223000563-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and prognostic analysis of the blastoid variant of mantle cell lymphoma: An analysis of 20 patients from two centers","authors":"Sai Huang ,&nbsp;Shaomei Liu ,&nbsp;Hongmei Jing ,&nbsp;Ping Chen ,&nbsp;Lili Dong ,&nbsp;Xiaoyu Hao ,&nbsp;Jian Bo ,&nbsp;Lu Sun ,&nbsp;Yu Zhao","doi":"10.1016/j.cpt.2023.10.007","DOIUrl":"10.1016/j.cpt.2023.10.007","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000897/pdfft?md5=fc420b70a7df102d6afbbf52030e46e3&pid=1-s2.0-S2949713223000897-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136127418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Despicable role of epithelial-mesenchymal transition in breast cancer metastasis: Exhibiting de novo restorative regimens","authors":"Paras Famta, Saurabh Shah, Biswajit Dey, Kondasingh Charan Kumar, Deepkumar Bagasariya, Ganesh Vambhurkar, Giriraj Pandey, Anamika Sharma, Dadi A. Srinivasarao, Rahul Kumar, Santosh Kumar Guru, R. Raghuvanshi, Saurabh Srivastava","doi":"10.1016/j.cpt.2024.01.001","DOIUrl":"https://doi.org/10.1016/j.cpt.2024.01.001","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer","authors":"Xue Feng ,&nbsp;Xiaolin Meng ,&nbsp;Dihong Tang ,&nbsp;Shuaiqingying Guo ,&nbsp;Qiuyue Liao ,&nbsp;Jing Chen ,&nbsp;Qin Xie ,&nbsp;Fengyuan Liu ,&nbsp;Yong Fang ,&nbsp;Chaoyang Sun ,&nbsp;Yingyan Han ,&nbsp;Jihui Ai ,&nbsp;Kezhen Li","doi":"10.1016/j.cpt.2023.07.003","DOIUrl":"10.1016/j.cpt.2023.07.003","url":null,"abstract":"<div><h3>Background</h3><p>Immunotherapy favors patients with tumors; however, only 3–26.3% of patients with cervical cancer benefit from single-agent immune checkpoint inhibitors. Combined immunotherapy and chemotherapy has been explored against tumor; however, the combination remains controversial. This study aimed to investigate the tumor immune microenvironment (TIME) and the effects of platinum-based neoadjuvant chemotherapy (NACT) in cervical cancer to identify the clinical value of combining chemotherapy with immunotherapy.</p></div><div><h3>Methods</h3><p>Multiplex immunohistochemistry (IHC) with 11 markers (cluster of differentiation [CD]3, CD8, CD4, CD11c, CD68, forkhead box P3 [Foxp3], programmed cell death 1 [PD-1], programmed cell death 1 ligand 1 [PD-L1], indoleamine 2,3-dioxygenase [IDO], cyclin-dependent kinase inhibitor 2A [p16], and cytokeratin [CK]) was performed to evaluate TIME from 108 matched pre- and post-NACT cervical cancer samples. The mechanism of antitumor immunity triggered by NACT was explored using RNA sequencing (RNA-seq) from four paired samples and subsequently verified in 41 samples using IHC.</p></div><div><h3>Results</h3><p>The infiltration rate of the CD8⁺ T cells in treatment-naive cervical cancer was 0.73%, and those of Foxp3⁺ regulatory T cells (Tregs) and IDO⁺ cells were 0.87% and 17.15%, respectively. Moreover, immunoreactive T cells, dendritic cells, and macrophages were more in the stromal than the intratumor region. NACT increased dendritic, CD3⁺ T, CD8⁺ T, and CD4⁺ T cells and decreased Tregs. The aforementioned alterations occurred predominantly in the stromal region and were primarily in responders. Non-responders primarily showed decreased Tregs and no increase in CD8⁺ T or dendritic cell infiltration. Furthermore, dendritic cells interacted more closely with CD3⁺ T cells after NACT, an effect primarily observed in responders. RNA-seq data revealed activation of the antigen receptor-mediated signaling pathway and upregulation of major histocompatibility complex (MHC) I and MHC II after chemotherapy, validated using IHC.</p></div><div><h3>Conclusions</h3><p>NACT can reduce Tregs, and when tumor cells are effectively killed, antigen presentation is enhanced, subsequently activating antitumor immunity finitely. Our study provides the molecular characteristics and theoretical basis for the simultaneous or sequential combination of platinum-based NACT and immunotherapy for cervical cancer.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000460/pdfft?md5=9c95ed1180f2b1c613ea514217561b19&pid=1-s2.0-S2949713223000460-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83898936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and toxicity of anlotinib plus camrelizumab versus anlotinib plus S-1 as second-line therapy for advanced esophageal squamous cell carcinoma: A real-world retrospective study","authors":"","doi":"10.1016/j.cpt.2023.12.003","DOIUrl":"10.1016/j.cpt.2023.12.003","url":null,"abstract":"<div><h3>Background</h3><div>No data exist on the efficacy and safety of anlotinib plus camrelizumab doublet as second-line therapy for advanced esophageal squamous cell carcinoma (ESCC). Although anlotinib and the programmed death-1 (PD-1) inhibitor camrelizumab are used as treatments for ESCC, the combined use of anlotinib and camrelizumab as a second-line therapy has not been reported. Therefore, this study explored the efficacy and toxicity of anlotinib plus camrelizumab as second-line therapy for advanced ESCC.</div></div><div><h3>Methods</h3><div>Fifty-eight patients with advanced ESCC undergoing second-line therapy, either with anlotinib plus camrelizumab or anlotinib plus S-1, were enrolled and retrospectively analyzed at Jiangsu Province Hospital of Chinese Medicine from January 2020 to December 2021. The primary endpoint was progression-free survival (PFS), with secondary endpoints including the objective response rate (ORR), disease control rate (DCR), and assessment of toxicity.</div></div><div><h3>Results</h3><div>In patients with advanced ESCC, the anlotinib plus camrelizumab group (<em>N</em> = 32) exhibited longer PFS (8.00 <em>vs.</em> 4.53 months, <em>P</em> &lt; 0.001), higher ORR (28.1 <em>vs.</em> 19.2%, <em>P</em> = 0.431), and higher DCR (87.5 <em>vs.</em> 65.4%, <em>P</em> = 0.045) than those in the anlotinib plus S-1 group (<em>N</em> = 26). Treatment-related adverse events (TRAEs) were predominantly grade 1/2 in both groups, with a higher incidence of grade 1/2 skin toxicity in patients treated with anlotinib plus camrelizumab (<em>P</em> = 0.033). Two patients (6.3%) developed grade 1/2 immune-related pneumonia. The incidence of grade 3/4 TRAEs did not differ significantly between the two groups. Multivariable Cox regression analysis identified that the drug regimen (<em>P</em> &lt; 0.001), Eastern Cooperative Oncology Group performance status (<em>P</em> = 0.008), and differentiation grade (<em>P</em> = 0.008) were independent prognostic factors for PFS.</div></div><div><h3>Conclusions</h3><div>Anlotinib plus camrelizumab exhibited promising antitumor efficacy and manageable toxicity when used as a second-line treatment for advanced ESCC.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223001064/pdfft?md5=795f6848529b655d76ae2f3a7a24bf94&pid=1-s2.0-S2949713223001064-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}